Fully Online Care
In-House RxDose Adjustments By Provider
Prescription IncludedYes
Telehealth IncludedYes
Online-Only OptionYes
Skip LabsNot Disclosed
- Flat-rate pricing
- Prescription included · 100% online · Dose adjustment supported
- Free shipping · Supplies included · Discreet packaging
- Tirzepatide, Semaglutide
- Available in all 50 states
- Auto-renewing plans · Cancellation terms apply
- Video consultation required · Other fees may apply
- Pharmacy data not disclosed
Provider Plans
Oral Plan
TirzepatideBundleShips UpfrontOral
Prepaid Sale$297/avg
PharmacyNot Disclosed (503A/B)
AdditivesNot Disclosed
PreservativeNot Disclosed
BUD (Shelf Life)Not Disclosed
BillingPaid Upfront
CommitmentNo Commitment
3-Month Prepaid
Other Fees$30 Consultation
Auto-RenewsYes
| DoseYour Supply | Your Price | Your Supply | Avg/mo | Your Value |
|---|---|---|---|---|
| 2.5mg/wk30mg/total | $891.00$1047.00 | 30mg | $297 | $29.70/mg |
| 5.0mg/wk60mg/total | $891.00$1047.00 | 60mg | $297 | $14.85/mg |
| 7.5mg/wk90mg/total | $891.00$1047.00 | 90mg | $297 | $9.90/mg |
| 10.0mg/wk120mg/total | $891.00$1047.00 | 120mg | $297 | $7.42/mg |
| 12.5mg/wk150mg/total | $891.00$1047.00 | 150mg | $297 | $5.94/mg |
| 15.0mg/wk180mg/total | $891.00$1047.00 | 180mg | $297 | $4.95/mg |
| Sale price included · Consultation fee not included | ||||
| $1,047 for a 3-month supply, or $891 if paid in full up front. | ||||
States Excluded From PackageNone
Provider Details
Self-Pay
CreditPrepaid Sale
Insurance AcceptedNo
HSA/FSA AcceptedNot Disclosed
Financing AvailableNot Disclosed
SaleYes
LegitScript Certified
Trustpilot 4.4
LegitScript CertifiedYes
HIPAA CompliantYes
Mobile AppNot Disclosed
Free Shipping
Supplies IncludedCold-Packed
Free ShippingYes
Expedited ShippingNot Disclosed
Discreet PackagingYes
Tirz + Sema · 503A
Formats: Injection · Oral Tablet
Offers TirzepatideYes
Offers SemaglutideYes
Offers BrandNo
Other TreatmentsYes
Contact & Support
Provider Notes
Compliance
The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.
General
Eligibility ages are stated as 18 to 70 on treatment pages and 18 to 80 on marketing landing pages.
A microdose semaglutide line (half-dose, twice-weekly) is offered in injectable and oral forms.